ANNVILLE, Pa.--(BUSINESS WIRE)--L2P Research Labs, a leading preclinical CRO, today announced its annual research accomplishments.
Dr. Suresh Anaganti, Chief Executive Officer of L2P Research Labs, shared contribution to preclinical data published in Cell Reports.
In addition to prestigious Cell Reports, L2P also announces its contribution to research work published in Sciences advances.
As a Contract Research Laboratory specialized in Immune oncology, we are happy to share that our Renal carcinoma tumor model has been used to study Alphataxin, a small molecule drug that elevates tumor infiltration of CD4+ T- cells.
L2P Research Labs brings unique capabilities and solid reputation in providing Preclinical Research services. Recently, L2P added 5,000 SFT GLP-compliant testing facility in Long Island, focused on providing Bioanalytical services.
About L2P Research Labs
L2P Research is a Pennsylvania based Research organization that provides integrated R&D support in all the key areas of pharmaceutical development. With a large worldwide customer base, L2P provides a complete array of research services as required for Investigational New Drug Applications (IND).
Ms. Kerry Lucas, Administrative Manager
L2P Research, LLC
51 Oxford Road
Annville, Pa 17003